1. Home
  2. ACET vs FRMM Comparison

ACET vs FRMM Comparison

Compare ACET & FRMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.38

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

FRMM

Forum Markets Incorporated Common Stock

N/A

Current Price

$5.50

Market Cap

65.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
FRMM
Founded
1947
N/A
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.3M
65.8M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
ACET
FRMM
Price
$7.38
$5.50
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$48.33
$5.00
AVG Volume (30 Days)
99.0K
327.0K
Earning Date
05-06-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$183.55
Revenue Next Year
N/A
$166.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.76
52 Week High
$9.47
$5.87

Technical Indicators

Market Signals
Indicator
ACET
FRMM
Relative Strength Index (RSI) 42.41 64.47
Support Level $6.28 $3.61
Resistance Level $8.68 $5.87
Average True Range (ATR) 0.54 0.46
MACD -0.15 0.08
Stochastic Oscillator 11.01 80.57

Price Performance

Historical Comparison
ACET
FRMM

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About FRMM Forum Markets Incorporated Common Stock

Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.

Share on Social Networks: